Drug Trial Radar · NCT07601386
Safety and Efficacy of JMKX000189 for Chemotherapy-Induced Peripheral Neuropathy
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
May 10, 2026
Primary completion
Jun 20, 2027
Study completion Jun 20, 2027
Sponsor
- Lead sponsor
- Shanghai Jeyou Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase Ib clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of JMKX000189 tablets in participants with chemotherapy-induced peripheral neuropathy (CIPN).
Conditions
- CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions
JMKX000189Drug
JMKX000189 administered orally.
PlaceboOther
Placebo administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).Time frame: up to 6 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital Fudan University
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.